Stem cell therapy for heart failure: Ensuring regenerative proficiency.
Stem cell therapy for heart failure: Ensuring regenerative proficiency.
复制标题
DOI：
10.1016/j.tcm.2016.01.003
复制
发表时间：
2016-07
影响因子：
9.3
通讯作者：
Behfar A
中科院分区：
文献类型：
--
作者：
Terzic A;Behfar A
患者来源的干细胞使有希望的再生策略成为可能，但显示出不同的心脏修复熟练程度，导致不可预测的治疗结果阻碍了实践的采用。因此，建立和证明新兴生物疗法的再生能力的手段是必要的。在这个临床组学的时代，临床试验中不同的细胞修复性能的去卷积提供了一个前所未有的机会来绘制区分再生和非再生状态的路径，从而通知心脏再生质量系统的演变。这种方法的第一个例子是为确保再生性能而开发的心脏生成介导的谱系规范。在临床前和早期临床研究中成功测试的心脏干细胞表型的安全性和有效性正在慢性缺血性心肌病的关键试验中得到验证，这为心力衰竭提供了下一代再生解决方案的前景。
Patient-derived stem cells enable promising regenerative strategies but display heterogenous cardiac reparative proficiency, leading to unpredictable therapeutic outcomes impeding practice adoption. Means to establish and certify the regenerative potency of emerging biotherapies are thus warranted. In this era of clinomics, deconvolution of variant cytoreparative performance in clinical trials offers an unprecedented opportunity to map pathways that segregate regenerative from non-regenerative states informing the evolution of cardioregenerative quality systems. A maiden example of this approach is cardiopoiesis-mediated lineage-specification developed to ensure regenerative performance. Successfully tested in pre-clinical and early clinical studies, the safety and efficacy of the cardiopoietic stem cell phenotype is undergoing validation in pivotal trials for chronic ischemic cardiomyopathy offering the prospect of a next-generation regenerative solution for heart failure.